Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
详细信息 查看全文
- 作者：Matthew P. Gilbert ; Richard E. Pratley
- 关键词：DPP-4 ; exenatide-LAR ; GLP-1 receptor agonist ; liraglutide ; sitagliptin
- 刊名：European Journal of Internal Medicine
- 出版年：2009
- 出版时间：July 2009
- 年：2009
- 卷：20
- 期：Supplement 2
- 页码：S309-S318
- 全文大小：544 K
文摘
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide–1 (GLP-1) receptor agonists and dipeptidyl peptidase–4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.